Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Terminal Care | 3 | 2021 | 447 | 1.170 |
Why?
|
| Oropharyngeal Neoplasms | 9 | 2022 | 1105 | 0.950 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 792 | 0.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2023 | 5319 | 0.780 |
Why?
|
| Palliative Care | 3 | 2021 | 2037 | 0.740 |
Why?
|
| Professional-Family Relations | 1 | 2021 | 134 | 0.730 |
Why?
|
| Goals | 1 | 2021 | 185 | 0.720 |
Why?
|
| Terminally Ill | 2 | 2012 | 91 | 0.620 |
Why?
|
| Advance Care Planning | 1 | 2018 | 86 | 0.600 |
Why?
|
| Head and Neck Neoplasms | 6 | 2022 | 3976 | 0.560 |
Why?
|
| Lung Neoplasms | 10 | 2023 | 11538 | 0.550 |
Why?
|
| Induction Chemotherapy | 2 | 2021 | 669 | 0.540 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2018 | 323 | 0.530 |
Why?
|
| Chemoradiotherapy | 3 | 2021 | 1946 | 0.440 |
Why?
|
| Attitude to Death | 1 | 2012 | 100 | 0.410 |
Why?
|
| Xerostomia | 2 | 2022 | 190 | 0.370 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2022 | 799 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.310 |
Why?
|
| Cranial Irradiation | 1 | 2008 | 315 | 0.280 |
Why?
|
| Physicians | 1 | 2012 | 882 | 0.240 |
Why?
|
| Mind-Body Relations, Metaphysical | 1 | 2003 | 3 | 0.230 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 833 | 0.210 |
Why?
|
| Tinnitus | 1 | 2022 | 38 | 0.210 |
Why?
|
| Spirituality | 1 | 2003 | 129 | 0.200 |
Why?
|
| Voice Disorders | 1 | 2021 | 39 | 0.200 |
Why?
|
| Speech Disorders | 1 | 2021 | 91 | 0.190 |
Why?
|
| Hearing Loss | 1 | 2022 | 153 | 0.190 |
Why?
|
| B7-H1 Antigen | 3 | 2023 | 1022 | 0.190 |
Why?
|
| Carboplatin | 1 | 2003 | 823 | 0.190 |
Why?
|
| Trismus | 1 | 2020 | 24 | 0.190 |
Why?
|
| Cancer Survivors | 3 | 2022 | 650 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 425 | 0.170 |
Why?
|
| Patient Care Planning | 1 | 2021 | 297 | 0.170 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 82 | 0.170 |
Why?
|
| Humans | 30 | 2024 | 261506 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2024 | 493 | 0.170 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2023 | 421 | 0.170 |
Why?
|
| Neoplasms | 2 | 2024 | 15193 | 0.170 |
Why?
|
| Mucositis | 1 | 2019 | 148 | 0.160 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 764 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2003 | 1353 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.160 |
Why?
|
| Exons | 1 | 2021 | 1328 | 0.150 |
Why?
|
| Aged | 12 | 2023 | 70117 | 0.140 |
Why?
|
| Quinazolines | 1 | 2021 | 923 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2021 | 710 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 476 | 0.140 |
Why?
|
| Male | 14 | 2024 | 123000 | 0.130 |
Why?
|
| Quality of Life | 4 | 2022 | 4532 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 15862 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 10035 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 5437 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2018 | 624 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4654 | 0.120 |
Why?
|
| Hypertension | 1 | 2024 | 1503 | 0.120 |
Why?
|
| Middle Aged | 11 | 2021 | 86204 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 1215 | 0.120 |
Why?
|
| Female | 14 | 2022 | 141928 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2022 | 32848 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 1226 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2020 | 2054 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 980 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3251 | 0.100 |
Why?
|
| Survivors | 3 | 2022 | 1031 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1559 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2518 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4314 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4849 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2022 | 37905 | 0.090 |
Why?
|
| Carcinoma | 1 | 2022 | 2578 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2021 | 2104 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 29902 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2024 | 1021 | 0.080 |
Why?
|
| Adult | 7 | 2021 | 77950 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 13658 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 4975 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2023 | 12873 | 0.060 |
Why?
|
| Risk Factors | 4 | 2022 | 17523 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7551 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.050 |
Why?
|
| World Health Organization | 1 | 2003 | 316 | 0.050 |
Why?
|
| Phototherapy | 1 | 2021 | 75 | 0.050 |
Why?
|
| Self Concept | 1 | 2003 | 211 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 14289 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 224 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 1290 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2020 | 9180 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 472 | 0.040 |
Why?
|
| Young Adult | 1 | 2018 | 21445 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2003 | 465 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 487 | 0.040 |
Why?
|
| Prognosis | 3 | 2021 | 21713 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2003 | 785 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2022 | 862 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 2231 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 585 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 1533 | 0.040 |
Why?
|
| Adolescent | 1 | 2018 | 31252 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 3472 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 14889 | 0.040 |
Why?
|
| Steroids | 1 | 2019 | 356 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2003 | 795 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 306 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 756 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8865 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 1239 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 2432 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 3260 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1586 | 0.030 |
Why?
|
| Disease Progression | 1 | 2003 | 6682 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4367 | 0.020 |
Why?
|
| Time Factors | 1 | 2003 | 12926 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5687 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 5539 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12221 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 2594 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 3151 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 10331 | 0.010 |
Why?
|